Protein Design Labs, Inc.
Records under this name other than patents Protein Design Labs, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Protein Design Labs, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,709,610 | Therapeutic Use of ANTI-CS1 Antibodies Formerly held In force · Low confidence | In force | Low confidence | |
| US 7,399,469 | ANTI-LFL2 Antibodies for the Diagnosis, Prognosis and Treatment of Cancer Formerly held Term ended Term ended Mar 29, 2026 · High confidence | Term ended | Term ended Mar 29, 2026 | High confidence |
| US 10,442,859 | Therapeutic Use of ANTI-CS1 Antibodies Formerly held Term ended Term ended Aug 19, 2025 · Medium confidence | Term ended | Term ended Aug 19, 2025 | Medium confidence |
| US 7,276,372 | Antibodies Against GPR64 and Uses Thereof Formerly held Term ended Term ended Jun 22, 2025 · High confidence | Term ended | Term ended Jun 22, 2025 | High confidence |
| US 7,276,589 | Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis Formerly held Term ended Term ended Jan 11, 2025 · High confidence | Term ended | Term ended Jan 11, 2025 | High confidence |
| US 7,217,798 | Alteration of Fc-Fusion Protein Serum Half-Lives by Mutagenesis Formerly held Term ended Ended no later than Oct 15, 2024 · Medium confidence | Term ended | Ended no later than Oct 15, 2024 | Medium confidence |
| US 7,285,268 | Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis Formerly held Term ended Term ended Sep 19, 2024 · High confidence | Term ended | Term ended Sep 19, 2024 | High confidence |
| US 7,288,248 | Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof Formerly held Term ended Term ended Sep 1, 2024 · High confidence | Term ended | Term ended Sep 1, 2024 | High confidence |
| US 7,189,507 | Methods of Diagnosis of Ovarian Cancer, Compositions and Methods of Screening for Modulators of Ovarian Cancer Formerly held Term ended Term ended Jul 12, 2024 · High confidence | Term ended | Term ended Jul 12, 2024 | High confidence |
| US 7,122,185 | ANTI-CCR5 Antibody Formerly held Term ended Term ended Jun 1, 2024 · High confidence | Term ended | Term ended Jun 1, 2024 | High confidence |